(The Washington Post, 04-03-17)
Here’s a simple reason crafting health policy is so devilishly hard: Most Americans are pretty healthy and a few are really sick.
wo new drugs were cleared to hit the market last week: an eczema drug that will cost $37,000 per year and one for multiple sclerosis that will cost $65,000.
(The New York Times, 03-29-17)
The catastrophe struck Wanda Wickizer on Christmas Day 2013.
(The New York Times, 03-28-17)
Doctors who tend to spend more in treating hospitalized patients do not get better results than those who spend less, a new study has found.
(The Huffington Post, 03-27-17)
Cameron Credle was barely more than a toddler when he was diagnosed with abnormally high cholesterol.
Telehealth takes a lot of forms these days. Virtual visits with a health care provider can take place by video, phone or text, or via the Web or a mobile app.
(News & Observer, 03-24-17)
A group of North Carolina House legislators, hoping to make it harder for teens to get addicted to nicotine, wants to raise the minimum age for buying cigarettes and vaping products to 21.
Acting on a request from three influential U.S. senators, the government’s accountability arm confirmed Tuesday that it will investigate potential abuses of the Orphan Drug Act.
(Kaiser Heath New, 03-20-17)
Laura Ries was moved to action when she saw a TV commercial that portrayed a woman enjoying time with her grandchildren after taking Lyrica, a prescription medication for diabetic nerve pain. Ries’ elderly mother suffered from just that problem.
(The Huffington Post, 03-16-17)
For years Americans with Duchenne muscular dystrophy were able to import a drug, deflazacort, from outside the United States at a cost of about $1,200 per year.
(Kaiser Health News, 3-16-17)
Marathon Pharmaceuticals’ controversial $89,000-a-year drug that has drawn outrage from patients and intense questioning from Congress is getting a new owner.
(The News & Observer, 3-16-17)
North Carolinians are healthier than their neighbors in South Carolina, but not as healthy as the residents of 33 other states and the District of Columbia.
John Krahne received alarming news from his doctor last December. His brain tumors were stable, but his lung tumors had grown noticeably larger. The doctor recommended a drug calledAlecensa, which sells for more than $159,000 a year. Medicare would charge Krahne a $3,200 copay in December, then another $3,200 in January, as a new year of coverage kicked in.
For the first time since being diagnosed 10 years ago, Krahne, 65, decided to delay filling his prescription, hoping that his cancer wouldn’t take advantage of the lapse and wreak further havoc on his body.
(Modern Healthcare, 3-14-17)
If left unchecked, the rising cost of cancer drugs could have devastating implications for individuals, societies and national economies, a group of cancer physicians and researchers said.
(The New York Times, 03-08-17)
Sometimes doctors choose to do surgery not because it is absolutely preferable to other treatments but because they get reimbursed for it, a new study suggests.
(The Washington Post, 03-08-17)
Maine Sen. Susan Collins is among a group of senators that wants to make sure senior citizens aren’t charged with unexpected bills after a colonoscopy.
(The Washington Post, 03-05-17)
Medical expenses are a burden whenever they hit, but a recent study found they’re most common around this time of year.
(The Hill, 03-03-17)
States are responding to increasing drug costs with legislation that would subject drugmakers to more scrutiny over their pricing.
(Kaiser Family Foundation, 03-02-17)
As lawmakers debate the future of the country’s health care system and outline plans to repeal and replace the Affordable Care Act, much of the current debate surrounds how to change or eliminate the health insurance marketplaces developed under the ACA where individuals eligible for financial assistance could compare plans and purchase insurance.
(The Wall Street Journal, 2-26-17)
Facing mounting criticism about prices, drug companies put some limits on their increases this year.
(Kaiser Health News, 2-16-17)
The latest flashpoint in the ongoing debate over high drug prices is Emflaza, an $89,000-a-year drug that treats Duchenne muscular dystrophy.
(The New York Times, 2-15-17)
The cost of medical care in the United States is expected to grow at a faster clip over the next decade and overall health spending growth will outpace that of the gross domestic product, a U.S. government health agency said on Wednesday.
(The Washington Post, 2-15-17)
U.S. health-care spending grew 4.8 percent last year, as the country has emerged from a period of historically low health spending growth, according to new federal estimates.
(Modern Healthcare, 2-11-17)
The just-departed commissioner of the Food and Drug Administration has concerns about plans to speed up drug approvals and dramatically reduce regulations at the agency, as advocated recently by President Donald Trump.
(Bloomberg BNA, 2-10-17)
Sicker-than-expected Obamacare enrollees caused many insurers to lose money and leave the exchanges, increasing premiums for remaining enrollees.
(Business Insider, 2-9-17)
Out-of-pocket healthcare costs in the US areamong the fastest-growing expensesfor Americans, and they can be devastating.
In 1971, the Food and Drug Administration approved the first drug that could reverse a heroin or opioid overdose. More than 40 years later, makers of this drug, callednaloxone, are cashing in on the nation’sopioid painkiller and heroin epidemicand price-gouging consumers.
When you have your health, your health-care costs in retirement will be high. And when you do not have your health, those costs will be even higher.
Uninsured rates in low-income families have fallen under the Affordable Care Act, yet more than a third of Americans continued to face difficulties paying their medical bills in 2016, a survey found.
(Washington Post, 1-27-17)
American health-care spending, measured in trillions of dollars, boggles the mind. Last year, we spent $3.2 trillion on health care — a number so large that it can be difficult to grasp its scale.
(The Hill, 1-26-17)
Everyone talks about how healthcare costs are rising. But there are ways for you to control your healthcare costs. Here are eight such ways.
(The Wall Street Journal, 1-25-17)
With Congress now reconsidering rules affecting the U.S. health-insurance system, it’s worth taking a look at what lawmakers are up against: an expensive health-care network that doesn’t deliver the best results to the most people at the lowest cost.
(The New York Times, 1-23-17)
American life spans are rising, and as they are, health care spending is, too. But longevity is not contributing to the spending increase as much as you might think.
(Business Insider, 1-23-17)
It’s shaping up to be another rough year for the drug industry.
(Kaiser Health News, 12-20-16)
As drug prices have spiraled upward in the past decade, tens of millions of generally law-abiding Americans have committed an illegal act in response: They have bought prescriptions outside the U.S. and imported them.
(The Hill, 12-19-16)
Doctors commonly prescribe drugs to treat conditions the medications weren’t designed for, but for drugmakers, discussing such “off-label” uses can lead to trouble.
(Harvard Business Review, 12-12-16)
The starting point for achieving value in any health care system is to measure outcomes.
(Yahoo News, 12-04-16)
The pace of U.S. health care spending picked up slightly last year, reaching a total of $3.2 trillion or $9,990 per person in the country. While a number of factors were at play, the increase was largely due to expanded coverage of individuals who signed up for Obamacare or who took advantage of a major expansion of Medicaid, according to a new study released on Friday.